# Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens

> **NCT07683000** · PHASE3 · RECRUITING · sponsor: **Gilead Sciences** · enrollment: 590 (estimated)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Lenacapavir
- **DRUG:** Lenacapavir Tablet
- **DRUG:** Teropavimab
- **DRUG:** Zinlirvimab
- **DRUG:** SBR

## Key facts

- **NCT ID:** NCT07683000
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-14
- **Primary completion:** 2029-03
- **Final completion:** 2033-03
- **Target enrollment:** 590 (ESTIMATED)
- **Last updated:** 2026-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07683000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07683000, "Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07683000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*